id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-3326-0030,FDA,FDA-2015-N-3326,"Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for
Comments",Notice,Request for Comments,2020-10-30T04:00:00Z,2020,10,2020-10-30T04:00:00Z,2020-12-20T04:59:59Z,2020-12-19T02:01:51Z,2020-24028,0,0,0900006484941712